Amgen (AMGN) Stock Analysis & AI Equity Report
Amgen (AMGN) overview
Amgen (AMGN) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 36,751m and operating profit of USD 9,080m; the year-end share price was 327.31 USD and market capitalisation was USD 176,355m. Amgen is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Amgen's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Amgen
Amgen discovers, develops, manufactures, and delivers human therapeutic medicines. Its products address diseases and areas of medical need, with examples in the filing including treatments for cardiovascular risk, IgG4-related disease, generalized myasthenia gravis, small cell lung cancer, chronic rhinosinusitis with nasal polyps, and thyroid eye disease. The company serves patients and healthcare providers through its medicines across markets worldwide.
Generate the Amgen report
Amgen is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Amgen and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Amgen
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.